Navigation Links
InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
Date:5/16/2011

on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union in adults for the treatment of mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to commercial launch preparations, anticipated timing of commercial launch and statements regarding the various anticipated durations of patent protection and marketing exclusivity.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the foll
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
2. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
3. InterMune to Release First Quarter Financial Results on April 28
4. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
5. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
6. InterMune to Release Third Quarter Financial Results on October 28
7. InterMune Sells Danoprevir Rights to Roche for $175 Million
8. InterMune to Present at 2010 Citi Health Care Conference
9. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
10. InterMune to Release First Quarter Financial Results on April 29
11. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ...
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... ... addition to the traditional pin connection, Tekscan is now offering a lower-cost termination method to ... , ... 30, 2010 -- Tekscan, Inc. announces a new lower-cost connection option for its custom ...
... ... the effect of HGH on athletes and other users sports performance , ... Copenhagen, Denmark (PRWEB) June 30, 2010 -- ... improve a sportsman’s physical performance., , ,However, few researchers from Denmark revealed that the level ...
... taken the first steps toward reducing the size and ... frequency spectrum. By combining a detector and laser ... the researchers rendered unnecessary the precision alignment of optical ... detector. The new solid-state system puts to use ...
Cached Biology Technology:Lower-Cost ZIF and LIF-Compatible Connection Option for Tekscan Custom Force Sensors 2Recent Study Reports Reveals that HGH May Aid Performance 2Sandia Labs reports first monolithic terahertz solid-state transceiver 2
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... SecurePad with Fingerprint Sensor Recognized in the ... Enabling Technologies Product Category, ... SYNA ), a leading developer of human interface ... that,its SecurePad(TM) solution has been selected as a CES ...
... Cranberry sauce is not the star of the traditional ... benefits, the lowly condiment takes center stage. In fact, ... compounds in cranberries are able to alter E. coli ... illnesses (from kidney infections to gastroenteritis to tooth decay), ...
... A major study that will provide a new window ... by the La Jolla Institute for Allergy & Immunology ... five-year study, funded by the National Institute of Allergy ... of Health, could lead to revolutionary new approaches for ...
Cached Biology News:Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree 2Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree 3Cranberry sauce: good for what ails you 2Cranberry sauce: good for what ails you 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... The FastPlax Antibody is used to ... on the surface of infected cells as ... the basis of the FastPlax Titer Kit, ... just 25-48 hours. The FastPlax ...
Biology Products: